Investigational drug · Phase 2
luxdegalutamide
Also called: JSB462, ARV-766
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostatic Cancer, Castration-Resistant, Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer Metastatic.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "luxdegalutamide"
First trial start
2021
Sep 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "luxdegalutamide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostatic Cancer, Castration-Resistant
- Progressive Metastatic Castrate Resistant Prostate Cancer
- Prostate Cancer Metastatic
- Metastatic Hormone-sensitive Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "luxdegalutamide" as an intervention, largest first.
Novartis PharmaceuticalsNovartis (NVS)
NCT07206056 · 188 participants (planned) · Start Oct 15, 2025 · Primary completion Nov 9, 2029
Drug: Tulmimetostat DL1 QD; Tulmimetostat DL2 QD and 7 more · For: Progressive Metastatic Castrate Resistant Prostate Cancer
Sites: Denver, Colorado; Jacksonville, Florida; Atlanta, Georgia · 35 sites in all
- An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06991556 · 168 participants · Start Jul 7, 2025 · Primary completion Dec 3, 2026
Drug: JSB462; Abiraterone and 1 more · For: Metastatic Hormone-sensitive Prostate Cancer
Sites: La Jolla, California; Santa Monica, California; Denver, Colorado · 64 sites in all
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate CancerPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05067140 · 164 participants · Start Sep 2, 2021 · Primary completion May 25, 2027
Drug: ARV-766; Abiraterone and 1 more · For: Prostate Cancer Metastatic
Sites: Duarte, California; La Jolla, California; Santa Monica, California · 17 sites in all
- A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07047118 · 138 participants · Start Jul 3, 2025 · Primary completion Jul 16, 2027
Drug: JSB462; AAA617 · For: Prostatic Cancer, Castration-Resistant
Sites: Duarte, California; Santa Monica, California; Denver, Colorado · 44 sites in all
- A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07174063 · 6 participants · Start Nov 26, 2025 · Primary completion Jan 29, 2027
Drug: JSB462 · For: Metastatic Prostate Cancer (mCRPC)
Sites: Nagoya, Japan; Kobe, Japan; Bunkyo Ku, Japan · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer.
Zhang Y, Ming A, Wang J, et al. · Pharmacol Res 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.